Unknown

Dataset Information

0

Brentuximab Vedotin in CD30+ Lymphomas.


ABSTRACT: Monoclonal antibodies (mAb) have become an effective treatment strategy for hematologic malignancies. CD30 is a rational target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin's lymphoma (cHL) and anaplastic large-cell lymphoma (ALCL). Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, utilizes the targeting properties of mAb to deliver a cytotoxic agent inside the malignant cell. Brentuximab vedotin has significant clinical activity in patients with relapsed or refractory cHL and relapsed or refractory ALCL, and has the potential to represent a significant advance in modern oncology.

SUBMITTER: Perini GF 

PROVIDER: S-EPMC3873074 | biostudies-other | 2013

REPOSITORIES: biostudies-other

altmetric image

Publications

Brentuximab Vedotin in CD30+ Lymphomas.

Perini Guilherme Fleury GF   Pro Barbara B  

Biologics in therapy 20130301


Monoclonal antibodies (mAb) have become an effective treatment strategy for hematologic malignancies. CD30 is a rational target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin's lymphoma (cHL) and anaplastic large-cell lymphoma (ALCL). Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, utilizes the targeting properties of mAb to deliver a cytotoxic agent inside the malignant cell. Brentuximab vedoti  ...[more]

Similar Datasets

| S-EPMC10394544 | biostudies-literature
| S-EPMC3278552 | biostudies-literature
| S-EPMC518847 | biostudies-literature
| S-EPMC9313053 | biostudies-literature
| S-EPMC10664184 | biostudies-literature
| S-EPMC5923348 | biostudies-literature
| S-EPMC5830626 | biostudies-literature
| S-EPMC5946765 | biostudies-literature
| S-EPMC3912476 | biostudies-other
| S-EPMC9503567 | biostudies-literature